Investors Alert: Oramed Pharmaceuticals Inc. (NASDAQ:ORMP), Cynapsus Therapeutics (NASDAQ:CYNA), Vical Incorporated (NASDAQ:VICL), CONMED Corporation (NASDAQ:CNMD), Infosys Ltd. (NYSE:INFY)

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) belongs to Healthcare sector. Its weekly performance is 1.01%. On last trading day company shares ended up $7.02. Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) distance from 50-day simple moving average (SMA50) is 4.86%. On 30 June, Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) announced that the first patient has been screened in the Company’s Phase IIb trial of its oral insulin capsule, ORMD-0801. This U.S. based study will be performed under the active Investigational New Drug (IND) application on file with the U.S. Food and Drug Administration (FDA).

Cynapsus Therapeutics (NASDAQ:CYNA) shares remains unchanged in last trading session and ended the day at $16.69. Cynapsus Therapeutics (NASDAQ:CYNA) quarterly performance is -0.65%. On 29 June, Cynapsus Therapeutics Inc. (NASDAQ:CYNA) announced enrollment of the first patient in the CTH-300 clinical trial, a pivotal Phase 3 study to examine the efficacy, safety and tolerability of APL-130277 for the acute treatment of OFF episodes in patients with Parkinson’s disease (PD).

On 10 July, Vical Incorporated (NASDAQ:VICL) shares decreased -0.14% and was closed at $0.70. VICL EPS growth in last 5 year was 20.80%. Vical Incorporated (NASDAQ:VICL) year to date (YTD) performance is -33.43%. On 22 June, Vical Incorporated (NASDAQ:VICL) announced top-line results from an ongoing randomized, double-blind, placebo controlled Phase 1/2 clinical study of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients.

CONMED Corporation (NASDAQ:CNMD) ended the last trading day at $58.49. Company weekly volatility is calculated as 2.24% and price to cash ratio as 24.57. CONMED Corporation (NASDAQ:CNMD) showed a weekly performance of -0.12%. On 7 July, CONMED Corporation (NASDAQ: CNMD) announced that it has added David Bronson and John L. Workman to its Board of Directors, effective immediately.

Infosys Ltd. (NYSE:INFY) shares advanced 0.45% in last trading session and ended the day at $15.48. INFY Gross Margin is 38.40% and its return on assets is 20.00%. Infosys Ltd. (NYSE:INFY) quarterly performance is -13.48%. Infosys Ltd. (NYSE:INFY) will now offer the Finacle suite of software solutions on Verizon Cloud. The fully integrated Finacle Core and Digital banking solutions, currently serving over 547 million consumers worldwide, are now available in a Software-as-a-Service (SaaS) model for community financial institutions in the U.S.

Leave a Reply

Your email address will not be published. Required fields are marked *